Stacie Dusetzina, PhD, Professor of Health Policy, Ingram Professor of Cancer Research, Vanderbilt University Medical Center, makes her long-awaited return to the show to cover all things related to pharmacy benefit managers. Stacie talks about the good, the bad, and the ugly, starting with the history of the PBMs and how they grew within the healthcare industry. What exactly is the role of the PBMs and why do they exist? Have they helped in reducing cost of care, and if not, why? Why are they heavily criticized? Stacie, as always, articulates the facts and separates the signal from noise.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
